Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Does one week of 10mg vs. 40mg Rosuvastatin improve skin microvascular blood flow in stable non-ST segment elevation myocardial infarction (NSTEMI) and healthy controls? A pilot study.

Trial Profile

Does one week of 10mg vs. 40mg Rosuvastatin improve skin microvascular blood flow in stable non-ST segment elevation myocardial infarction (NSTEMI) and healthy controls? A pilot study.

Status: Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 16 Jul 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rosuvastatin (Primary)
  • Indications Acute coronary syndromes; Arteriosclerosis; Cardiovascular disorders; Heart failure; Hypercholesterolaemia; Hyperlipidaemia; Myocardial infarction; Stroke
  • Focus Pharmacodynamics
  • Most Recent Events

    • 24 Mar 2018 Status changed from not yet recruiting to withdrawn prior to enrolment.
    • 08 Jun 2016 Planned initiation date changed from 1 Jul 2013 to 1 Jan 2016.
    • 14 Aug 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top